A blood test-derived skeletal muscle index combined with handgrip strength identifies a sarcopenia-related high-risk phenotype in non-dialysis-dependent chronic kidney disease

Clicks: 14
ID: 329746
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #189 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Sarcopenia is associated with adverse outcomes in CKD, but direct assessment of skeletal muscle mass is not always available. We examined whether serum creatinine- and cystatin C-derived estimated skeletal muscle index (SMI), combined with handgrip strength, identifies a sarcopenia-related high-risk phenotype in non-dialysis-dependent CKD. Methods We derived a new equation for appendicular skeletal muscle mass using bioelectrical impedance analysis as the reference in 100 patients with non-dialysis-dependent CKD. In an independent multicenter cohort of 1,403 patients, SMI was estimated using this equation and a published creatinine-cystatin C-based formula. The sarcopenia-related high-risk phenotype was defined as low handgrip strength plus low estimated SMI using sex-specific cutoffs. Outcomes were all-cause, cardiovascular, and non-cardiovascular mortality. Results During 5 years, 173 patients died, including 43 from cardiovascular causes. Low estimated SMI was identified in 218 patients (15.5%) with the published formula and 312 (22.2%) with the new equation; the corresponding phenotype prevalences were 11.9% and 11.7%. The phenotype was independently associated with all-cause mortality using either formula: adjusted hazard ratios were 1.54 (95% confidence interval [CI], 1.07-2.21) for the published formula and 2.14 (95% CI, 1.52-3.00) for the new equation. Four-category and sensitivity analyses yielded consistent findings. Conclusions Combining handgrip strength with creatinine- and cystatin C-derived estimated SMI identifies a sarcopenia-related high-risk phenotype and stratifies mortality risk in non-dialysis-dependent CKD. This approach may support screening when direct muscle mass assessment is unavailable but requires further validation before use as a diagnostic substitute.
Reference Key
openalex_W7214315383 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shunsuke Yamada, Shigeru Tanaka, Kenji Harada, Hisako Yoshida, Hiromasa Kitamura, Hokuto Arase, Masumi Shojima, Kazuhiko Tsuruya, Toshiaki Nakano, Tetsuro Ago
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag336
URL
https://doi.org/10.1093/ckj/sfag336
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.